259 filings
Page 3 of 13
8-K
xumpqf1
10 May 22
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
8-K
pvdkl q7n9a3wr7
22 Mar 22
Unregistered Sales of Equity Securities
4:04pm
8-K
ztcio5x 1mjvxbdzti
10 Mar 22
Results of Operations and Financial Condition
4:09pm
424B5
shjjolvcmu3xclcm64
1 Mar 22
Prospectus supplement for primary offering
5:12pm
8-K
5u8z207 o3bc995fkc
1 Mar 22
Entry into a Material Definitive Agreement
4:41pm
8-K
usciudh
1 Mar 22
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
12:00am
8-K
18qcr1zp3szn8ohh1
12 Jan 22
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
8:04am
8-K
8hd4nhb6siqox2
1 Dec 21
Entry into a Material Definitive Agreement
4:02pm
8-K
fmkhq79g
10 Nov 21
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:14pm
424B5
wuhzr7
6 Oct 21
Prospectus supplement for primary offering
5:05pm
8-K
6pjm9g4dr3 jl4xig615
6 Oct 21
Other Events
4:50pm
FWP
fmio97vu6vs4
5 Oct 21
Free writing prospectus
4:34pm
424B5
z5ijx2
4 Oct 21
Prospectus supplement for primary offering
5:27pm
S-3ASR
i7vfehbi
4 Oct 21
Automatic shelf registration
4:02pm
8-K
r5ssrbs
4 Oct 21
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
7:03am
8-K
03tlthj5pt3wzm0
8 Sep 21
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
8:32am